Drug interactions with new hepatitis C oral drugs

Expert Opinion on Drug Metabolism and Toxicology

Volumn 11, Issue 3, 2015, Pages 333-341

  Soriano, Vincent ^a   Labarga, Pablo ^b   Barreiro, Pablo ^a   Fernandez Montero, José V ^c   De Mendoza, Carmen ^d   Esposito, Isabella ^a   Benítez Gutiérrez, Laura ^d   Peña, José M ^a  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^b La Luz Clinic   (Spain)

^c CROSSHOUSE HOSPITAL   (United Kingdom)

^d HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

Author keywords

Daclatasvir; Ledipasvir; Ombitasvir; Paritaprevir; Simeprevir; Sofosbuvir

Indexed keywords

ANTIVIRUS AGENT; CYTOCHROME P450; DIRECT ACTING ANTIVIRAL AGENT; NONSTRUCTURAL PROTEIN 5A INHIBITOR; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; UNCLASSIFIED DRUG;

CLINICAL PRACTICE; DRUG EXPOSURE; DRUG INTERACTION; DRUG METABOLISM; HEPATITIS C; HUMAN; KIDNEY FAILURE; LIVER CIRRHOSIS; REVIEW; DRUG EFFECTS; HEPATITIS C, CHRONIC; METABOLISM; ORAL DRUG ADMINISTRATION; RISK FACTOR;

HEPATITIS C VIRUS;

ADMINISTRATION, ORAL; ANTIVIRAL AGENTS; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; HEPATITIS C, CHRONIC; HUMANS; RISK FACTORS;

EID: 84923039704     PISSN: 17425255     EISSN: 17447607     Source Type: Journal    
DOI: 10.1517/17425255.2015.998997     Document Type: Review

References (47)

1. Gower E, Estes C, Blach S, et al. Global epidemiology and genotype distribution of the hepatitis C virus infection. J Hepatol 2014;61(Suppl 1):45-57
2. EASL. Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol 2014;60:392-420
3. EASL. Recommendations on treatment of hepatitis C 2014. J Hepatol 2014;61:373-95
4. Vispo E, Barreiro P, Soriano V. Pharmacokinetics of new oral hepatitis C antiviral drugs. Expert Opin Drug Metab Toxicol 2013;9:5-16
5. Stedman C. Current prospects for interferon-free treatment of hepatitis C in 2012. J Gastroenterol Hepatol 2013;28:38-45
6. Flisiak R, Jaroszewicz J, Parfieniuk-Kowerda A. Emerging treatments for hepatitis C. Expert Opin Emerg Drugs 2013;18:461-75
7. Lange C, Zeuzem S. Perspectives and challenges of interferon-free therapy for chronic hepatitis C. J Hepatol 2013;58:583-92
8. Gentile I, Buonomo A, Zappulo E, Borgia G. Interferon-free therapies for chronic hepatitis C: toward a hepatitis C virus free world? Expert Rev Anti Infect Ther 2014;12:763-73
9. Pawlotsky JM. New hepatitis C therapies: the toolbox, strategies, and challenges. Gastroenterology 2014;146:1176-92
10. Back D, Else L. The importance of drug-drug interactions in the DAA era. Dig Liver Dis 2013;45(Suppl 5):343-8
11. Chtioui H, Buclin T, Moradpour D. New hepatitis C treatments: pharmacological considerations and potential for drug interactions. Rev Med Suisse 2014;10:1600-4.
12. Jiménez-Nácher I, Alvarez E, Morello J, et al. Approaches for understanding and predicting drug interactions in HIV-infected patients. Expert Opin Drug Metab Toxicol 2011;7:457-77
13. Soriano V, Sherman K, Rockstroh J, et al. Challenges and opportunities for hepatitis C drug development in HIV-hepatitis C virus co-infected patients. AIDS 2011;25:2197-208
14. Seden K, Back D. Directly acting antivirals for hepatitis C and antiretrovirals: potential or drug-drug interactions. Curr Opin HIV/AIDS 2011;6:514-26
15. Rodriguez-Torres M. Focus on drug interactions: the challenge of treating hepatitis C virus infection with directacting antiviral drugs in the HIV-positive patient. Curr Opin Infect Dis 2013;26:50-7
16. Karageorgopoulos D, El-Sherif O, Bhagani S, Khoo S. Drug interactions between antiretrovirals and new or emerging direct-acting antivirals in HIV/HCV coinfection. Curr Opin Infect Dis 2014;27:36-45.
17. Barreiro P, Fernandez-Montero JV, de Mendoza C, et al. Towards hepatitis C eradication from the HIV-infected population. Antiviral Res 2014;105:1-7
18. Tischer S, Fontana R. Drug-drug interactions with oral anti-HCV agents and idiosyncratic hepatotoxicity in the liver transplant setting. J Hepatol 2014;60:872-84
19. Burger D, Back D, Buggisch P, et al. Clinical management of drug-drug interactions in HCV therapy: challenges and solutions. J Hepatol 2013;58:792-800.
20. Kiser J, Burton J, Everson G. Drug-drug interactions during antiviral therapy for chronic hepatitis C. Nat Rev Gastroenterol Hepatol 2013;10:596-606.
21. Gane E, Roberts S, Stedman C, et al. Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, doubleblind, placebo-controlled, dose-escalation trial. Lancet 2010;376:1467-75
22. Jensen D, O'Leary J, Pockros P, et al. Safety and efficacy of sofosbuvir-containing regimens for hepatitis C: realworld experience in a diverse, longitudinal observational cohort. AASLD 2014, Boston, MA. 7-11 November 2014 [abstract 45]. Hepatology 2014. Hepatology 2014;60:219A
23. Dieterich D, Bacon B, Flamm S, et al. Evaluation of sofosbuvir and simeprevir-based regimens in the TRIO network: academic and community treatment of a real world, heterogeneous population. AASLD 2014, Boston, MA. 7-11 November 2014 [abstract 46]. Hepatology 2014. Hepatology 2014;60:220A
24. Bourliere M, Sulkowski M, Omata M, et al. An integrated safety and efficacy analysis of >500 patients with compensated cirrhosis treated with ledipasvir/sofosbuvir with or without ribavirin. AASLD 2014, Boston, MA [abstract 82]. Hepatology 2014;60:239A
25. Pol S, Reddy R, Baykal T, et al. Interferon-free regimens of ombitasvir and ABT-450/r with or without ribavirin in patients with HCV genotype 4 infection: PEARL-1 study results. AASLD 2014, Boston, MA [abstract 1928]. Hepatology 2014;60(Suppl 4):1129A
26. Lawitz E, Gane E, Pearlman B, et al. Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with previous null response with or without cirrhosis (C-WORTHY): a randomised, open-label phase 2 trial. Lancet 2014. [Epub ahead of print]
27. You D, Pockros P. Simeprevir for the treatment of chronic hepatitis C. Expert Opin Pharmacother 2013;14:2581-9
28. Gentile I, Borgia F, Buonomo A, et al. ABT-450: a novel protease inhibitor for the treatment of hepatitis C virus infection. Curr Med Chem 2014;21:3261-70
29. Sofia M. Beyond sofosbuvir: what opportunity exists for a better nucleoside/nucleotide to treat hepatitis C?Antivir Res 2014;107:119-24
30. Soriano V, Vispo E, de Mendoza C, et al. Hepatitis C therapy with HCV NS5B polymerase inhibitors. Expert Opin Pharmacother 2013;14:1161-70
31. Gentile I, Buonomo A, Borgia G. Dasabuvir: A non-nucleoside inhibitor of NS5B for the treatment of hepatitis C virus infection. Rev Recent Clin Trials 2014. [Epub ahead of print]
32. Treviño A, de Mendoza C, Parra P, et al. Natural polymorphisms associated with resistance to new antivirals against HCV in newly diagnosed HIV-HCV-coinfected patients. Antivir Ther 2011;16:413-16
33. Aghemo A, De Francesco R. Daclatasvir: a team player rather than a prima donna in the treatment of hepatitis C. Gut 2014. [Epub ahead of print]
34. Gentile I, Buonomo A, Borgia F, et al. Ledipasvir: a novel synthetic antiviral for the treatment of HCV infection. Expert Opin Investig Drugs 2014;23:561-71
35. Stirnimann G. Ombitasvir (ABT-267), a novel NS5A inhibitor for the treatment of hepatitis C. Expert Opin Pharmacother 2014;15:2609-22
36. Gentile I, Buonomo A, Borgia G. Ombitasvir: a potent pan-genotypic inhibitor of NS5A for the treatment of hepatitis C virus infection. Expert Rev Anti Infect Ther 2014;12:1033-43
37. Labarga P, Barreiro P, Martin-Carbonero L, et al. Kidney tubular abnormalities in the absence of impaired glomerular function in HIV patients treated with tenofovir. AIDS 2009;23:689-96.
38. Rockstroh J, Puoti M, Rodriguez-Torres M, et al. Sofosbuvir and ribavirin therapy for the treatment of HIV/HCV coinfected patients with HCV GT1-4 infection: the PHOTON-1 and -2 trials. AASLD 2014, Boston, MA [abstract 195]. Hepatology 2014;60:295A
39. Sulkowski M, Hezode C, Gerstoft J, et al. Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTHY): a randomised, open-label phase 2 trial. Lancet 2014. [Epub ahead of print]
40. Sulkowski M. Hepatitis debrief. AASLD 2014, Boston, MA [abstract]. Hepatology 2014;60:86A
41. Stock P, Terrault N. HIV and liver transplantation: Hepatitis C is the last hurdle. Hepatology 2014. [Epub ahead of print]
42. Pellicelli A, Montalbano M, Lionetti R, et al. Sofosbuvir plus daclatasvir for post-transplant recurrent hepatitis C: potent antiviral activity but no clinical benefit if treatment is given late. Dig Liver Dis 2014;46:923-7
43. Kwo P, Mantry P, Coakley E, et al. An interferon-free antiviral regimen for HCV after liver transplantation. N Engl J Med 2014. [Epub ahead of print]
44. Asselah T, Bruno S, Craxi A. HCV cirrhosis at the edge of decompensation: will paritaprevir with ritonavir, ombitasvir, dasabuvir and ribavirin solve the need for treatment? J Hepatol 2014;61(6):1430-3
45. Poole R. Daclatasvir + Asunaprevir: first global approval. Drugs 2014;74:1559-71.
46. Khatri A, Dutta S, Marbury T, et al. The pharmacokinetics and safety of the DAA ABT-450/r, ombitasvir with/without dasabuvir in subjects with mild, moderate and severe renal impairment compared to subjects with normal renal function. AASLD 2014, Boston, MA [abstract 238]. Hepatology. 2014;60:320A
47. Choo Q, Kuo G, Weiner A, et al. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 1989;244:359-62